Sight Sciences, Inc. (SGHT) Stock Score, Valuation & Financial Research
Sight Sciences, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for SGHT
Sight Sciences, Inc. currently has a Wall Street Score of 20/100. The stored market price is $8.14. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Sight Sciences, Inc. does
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
SGHT financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $8.14
- Market capitalization:
- $442.9M
- Revenue:
- $79.6M
- Net income:
- $-37.3M
- Free cash flow:
- $-29.9M
- Cash:
- $85.0M
- Total debt:
- $41.8M
- EPS:
- -0.74
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 6/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-29.9M, showing cash burn in the current stored period.
- The balance sheet shows $85.0M of cash versus $41.8M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.1 points: SGHT increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SGHT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.